scholarly journals Effects of Melatonin on Salivary Levels of Cortisol and Sleep Quality of Hemodialysis Patients: A Randomized Clinical Trial

Author(s):  
Elham Hasannia ◽  
Firoozeh Derakhshanpour ◽  
Mohammad Ali Vakili

Objective: The aim of this study was to investigate the effects of exogenous melatonin on the quality of sleep in patients undergoing dialysis and to investigate its mechanism for the regulation of total circadian rhythm and salivary levels of cortisol in hemodialysis patients admitted to Pange Azar hospital in Gorgan in winter of 2017. Method: This was a double-blind randomized clinical trial. Samples were transferred to the laboratory by maintaining the cold chain. Then, the patients were divided into two groups. In a double-blind trial, one group received three mg melatonin and another group received placebo for two weeks at 10 PM. At the end of two weeks, sampling was performed to investigate the salivary level of cortisol under the same conditions. The research instrument was Pittsburgh questionnaire. Data were analyzed before and after intervention using SPSS 16 software. Results: Salivary levels of cortisol decreased significantly after the intervention in the melatonin group (melatonin: 1.40 ± 1.82 and placebo: 4.94 ± 4.43; P = 0.008). Salivary levels of cortisol in the morning after intervention were also lower in the melatonin group, but were not statistically significant (melatonin 3.99 ± 3.45 and placebo: 5.35 ± 4.9; P = 0.93). Also, the difference in salivary levels of cortisol at night and before and after intervention significantly decreased in melatonin group. PSQI difference (interventional dimension) and PSQI (before intervention) were significantly decreased in melatonin group (P = 0.0001). The rate of change in the subscales of sleep latency, sleep efficiency, and sleep disorders in the melatonin group than in the placebo group was significantly higher. Conclusion: Melatonin can be used as a safe and cost-effective treatment to improve sleep quality and can also reduce salivary cortisol increased in hemodialysis patients at night.

2018 ◽  
Vol 7 (2) ◽  
pp. 131-136 ◽  
Author(s):  
Shahdak Dadashpour ◽  
Minoo Sadat Hajmiri ◽  
Daem Roshani

Introduction: Poor sleep quality is common among hemodialysis patients and can potentially predict morbidity, mortality and quality of life in these patients. On the other hand, hemodialysis patients are encountered with vitamin C deficiency. Objectives: The purpose of this study was to determine the effect of intravenous vitamin C on sleep quality, itching and restless leg syndrome in hemodialysis patients. Patients and Methods: In this double-blind randomized clinical trial, 90 qualified hemodialysis patients were gone under investigation in Sanandaj in 2016. Patients randomly allocated in two equal intervention and control groups. The main measured outcome was the Pittsburg Sleep Quality Index (PSQI) which consists of seven components. At the end of each hemodialysis session, the intervention group received vitamin C vial (500 mg/5 cc) intravenously, three times a week for 8 weeks and the control group received normal saline as placebo in the same way. Data were collected at pretreatment and after 2 months of treatment. Additionally raises questions related to restless leg syndrome and was assessed by VAS scale for determining the incidence of pruritus. Data were analyzed by independent t test, paired t test, Wilcoxon and chi-square tests. Results: Around 52.2% of subjects were female and 47.8% were male and most of them were in the age group above 50 years old. Results showed a notable difference in the value of itching and restless leg syndrome between the two groups as these values decreased significantly in the intervention group (P=0.0001). There was also a great difference in the quality of sleep disorder in subjective sleep quality, sleep latency and daily function between the two groups and those disorders was significantly lower in the intervention group (P=0.0001). Conclusion: This study showed that intravenous vitamin C can effectively improve sleep quality, itching and restless legs syndrome in hemodialysis patients.


BioMedicine ◽  
2020 ◽  
Vol 10 (4) ◽  
pp. 42-48
Author(s):  
Razieh Mahmoudi ◽  
Somayeh Ansari ◽  
Mohammad Hosein Haghighizadeh ◽  
Nader Shakiba Maram ◽  
Simin Montazeri

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Somayeh Makaremnia ◽  
Marieh Dehghan Manshadi ◽  
Zahra Khademian

Abstract Background Thalassemia have a negative impact on the patients' psychological health and sleep quality. This study aimed to determine the effects of a positive thinking training program on hope and sleep quality of patients with thalassemia major. Methods This randomized clinical trial was conducted on 78 patients with thalassemia major including 36 males (46.2%) and 42 females (53.8%) with a mean age of 25.56 ± 29.6 in Iran. Subjects were randomly assigned into experimental and control groups. Experimental group received 16 h training based on positive thinking materials published by Martin Seligman. Control group received only usual programs. Data were collected at baseline, as well as immediately and one month after the intervention, using Snyder’s Hope Scale and the Pittsburgh Sleep Quality Index. Data analysis was performed using SPSS Software 18.0; statistical tests included the independent T-test, the Chi-square, Mann Whitney, and Friedman test. Significance level was set at 0.05 in this study. Results The experimental group had a significantly higher mean hope score compared to the control group immediately (45.38 ± 7.82 vs. 35.32 ± 5.54, P < 0.001) and one month following intervention (44.67 ± 3.47 vs. 35 ± .54, P < 0.001). Moreover, the mean sleep quality scores of the experimental group was significantly greater than that for control group immediately (5.35 ± 2.02 vs. 7 ± 2.4, P = 0.004) and one month after the intervention (4.23 ± 2.2 vs.7.02 ± 3.03, P < 0.001). Conclusion Since our training program on positive thinking improved hope and quality of sleep in patients with thalassemia major, we recommend the use of such courses as an important step toward promotion of hope and sleep quality among these patients. Trial registration The name of the registry: Iranian Registry of Clinical Trials. Trial Registration Number: IRCT2017010431774N1. URL of the trial registry record: https://en.irct.ir/trial/24923. Registration Date: 07/03/2017.


2011 ◽  
Vol 64 (1) ◽  
pp. 24-31 ◽  
Author(s):  
Michael Hueppe ◽  
David Hartge ◽  
Klaus-Dieter Stoll ◽  
Andrea Ros ◽  
Peter Schmucker ◽  
...  

Author(s):  
Jordana Balbinot ◽  
Caroline Santana Real ◽  
Cecília Corte de Melo ◽  
Sílvia Dornelles ◽  
Sady Selaimen da Costa

Sign in / Sign up

Export Citation Format

Share Document